TriangleNCT01336634 · OUTCOME
Apparent Clearance (CL/F) of Dabrafenib
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- GEOMETRIC_MEAN
- Unit
- Liter/hour (L/hr)
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Week 3, Week 6, Week 12 and Week 18
What was measured
Blood samples from participants were collected for population pharmacokinetic analysis including the apparent base clearance (CL/F) following oral dosing of dabrafenib. Concentrations of dabrafenib was determined in plasma samples using the currently approved analytical methodology.
Analysis population: All subjects who received at least one dose of dabrafenib in the Cohort A (Dabrafenib Monotherapy) and in the doublets combination (Dabrafenib + Trametinib) Cohort B and C and provided an evaluable PK profile.
Groups in this outcome
Cohort A (Dabrafenib Monotherapy): Dabrafenib Monotherapy 150mg BID
Participants with or without prior systemic anti-cancer therapy received Dabrafenib 150 mg BID until disease progression, death, or unacceptable adverse event(s) (AEs) or investigator discretion to discontinue or decision to crossover from monotherapy to combination therapy.
Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD
Participants who had received 1-3 prior lines of systemic anti-cancer therapies for advanced stage/metastatic disease received Dabrafenib 150 mg BID and Trametinib 2 mg once daily (OD). Treatment continued until disease progression, death, or unacceptable AEs or investigator discretion to discontinue.
Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD
Participants who had not received any prior systemic anti-cancer for metastatic disease therapies were given Dabrafenib 150 mg BID and Trametinib 2 mg OD. Treatment continued until disease progression, death, or unacceptable AEs or at investigator discretion to discontinue.
| Group | Source count |
|---|---|
| Cohort A (Dabrafenib Monotherapy): Dabrafenib Monotherapy 150mg BID | 76 |
| Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD | 53 |
| Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD | 30 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Cohort A (Dabrafenib Monotherapy): Dabrafenib Monotherapy 150mg BID | 30.5 | Not reported | 29.1 | 32.0 | Not reported |
| Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD | 21.4 | Not reported | 19.37 | 23.70 | Not reported |
| Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD | 23.9 | Not reported | 22.02 | 25.87 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 29.1
- upper Limit
- 32.0
- value
- 30.5
- group Id
- OG001
- lower Limit
- 19.37
- upper Limit
- 23.70
- value
- 21.4
- group Id
- OG002
- lower Limit
- 22.02
- upper Limit
- 25.87
- value
- 23.9
- denoms
- counts
- group Id
- OG000
- value
- 76
- group Id
- OG001
- value
- 53
- group Id
- OG002
- value
- 30
- units
- Participants
- description
- Blood samples from participants were collected for population pharmacokinetic analysis including the apparent base clearance (CL/F) following oral dosing of dabrafenib. Concentrations of dabrafenib was determined in plasma samples using the currently approved analytical methodology.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants with or without prior systemic anti-cancer therapy received Dabrafenib 150 mg BID until disease progression, death, or unacceptable adverse event(s) (AEs) or investigator discretion to discontinue or decision to crossover from monotherapy to combination therapy.
- id
- OG000
- title
- Cohort A (Dabrafenib Monotherapy): Dabrafenib Monotherapy 150mg BID
- description
- Participants who had received 1-3 prior lines of systemic anti-cancer therapies for advanced stage/metastatic disease received Dabrafenib 150 mg BID and Trametinib 2 mg once daily (OD). Treatment continued until disease progression, death, or unacceptable AEs or investigator discretion to discontinue.
- id
- OG001
- title
- Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD
- description
- Participants who had not received any prior systemic anti-cancer for metastatic disease therapies were given Dabrafenib 150 mg BID and Trametinib 2 mg OD. Treatment continued until disease progression, death, or unacceptable AEs or at investigator discretion to discontinue.
- id
- OG002
- title
- Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD
- param Type
- GEOMETRIC_MEAN
- population Description
- All subjects who received at least one dose of dabrafenib in the Cohort A (Dabrafenib Monotherapy) and in the doublets combination (Dabrafenib + Trametinib) Cohort B and C and provided an evaluable PK profile.
- reporting Status
- POSTED
- time Frame
- Week 3, Week 6, Week 12 and Week 18
- title
- Apparent Clearance (CL/F) of Dabrafenib
- type
- SECONDARY
- unit Of Measure
- Liter/hour (L/hr)
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Independent clinical review pending · Not medical advice